144060-53-7 Febuxostat 99%

SCL was incorporated on December 20, 1993, as a Private Limited Company.  Initially, it manufactured intermediates.  On July 1, 1997, the company became a Public Limited Company and adopted its current name.  In 2004, SCL established a new API manufacturing facility.  Today, it offers a wide range of APIs and advanced intermediates in various therapeutic segments such as NSAIDs, cardiology, anti-cholinergic, CNS, anti-filarials, and anthelmintics, among others, to its customers.  We are based in Panchkula, near Chandigarh, with two manufacturing facilities in Derabassi, Mohali (Punjab), for intermediates and APIs.  The marketing office is located in Delhi NCR.  We have acquired 22 acres of land for expanding facilities near the current site.

SCL caters to both the domestic and international markets, with approximately 60% of the total revenue coming from the international market.
• We are engaged in manufacturing bulk drugs/APIs and advanced intermediates.
• We also specialize in providing CDMO services to clients in regulated markets in Europe, the USA, and Japan.